A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America

Active, not recruitingOBSERVATIONAL
Enrollment

64

Participants

Timeline

Start Date

July 21, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Ovarian Cancer
Interventions
OTHER

Observational study

This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

Trial Locations (16)

Unknown

COIP - Centro Oncologico Integral Pampeano, Santa Rosa

Sanatorio de la Mujer, Rosario

Fundacion Medica de Rio Negro y Neuquen, Neuquén

Pérola Byington Centro de Pesquisa, São Paulo

69.020-030

CINPAM - Centro Integrado de Pesquisa da Amazônia, Manaus

29.043-260

Hospital Santa Rita de Cássia, Vitória

40.170-110

NOB - Núcleo de Oncologia da Bahia (Oncoclínicas), Salvador

30.360-680

Oncocentro de Minas Gerais (Oncoclínicas), Belo Horizonte

80.040-170

IOP Pesquisa - Instituto de Oncologia do Paraná, Curitiba

90.035-000

HMV - Hospital Moinhos de Vento, Porto Alegre

90.610-000

CPO - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS, Porto Alegre

14.784-400

Hospital de Amor de Barretos, Barretos

17.210-120

Hospital Amaral Carvalho de Jaú, Jaú

01.246-000

ICESP - Instituto do Câncer do Estado de São Paulo, São Paulo

01.323-030

BP - A Beneficência Portuguesa de São Paulo, São Paulo

04.502-001

Instituto D'Or de Pesquisa e Ensino SP, São Paulo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Latin American Cooperative Oncology Group

OTHER